Abstract
Deguelin is the major active ingredient and principal component in cube resin, derived from Lonchocarpus utilis and used as a botanical insecticide and pesticide in Africa, South America and China. A growing body of evidence indicates that deguelin has a very strong anti-tumor effect on malignant cells without compromising normal cells. As a complex natural extract, deguelin interacts with various molecular targets to exert its anti-tumor properties at nanomolar levels. This current review delineates the molecular mechanism of the anti-tumor activities of deguelin in malignancies. Our research shows that the multiple and extensive biological effects of deguelin are mediated via interactions with target points involved in cell proliferation pathways (cyclin D1, pRb), cell apoptosis pathways (NF-κB, IκBα, Bcl-2, Bcl-xl, survivin), the nucleophosmin and nucleoporins pathways (Nup88, Nup98, Nup214), as well as through the regulation of steroid receptor co-activator SRC-3 and DNA Topoisomerase. In addition, deguelin holds a promising efficacy for reversing drug resistance.
Keywords: Anti-tumor, Bcl-xl, Bcl-2, Cyclin D1, Deguelin, IκBα, NF-κB, NPM, NUPs, pRb, SRC-3, Survivin
Current Pharmaceutical Analysis
Title: Molecular Mechanism of Deguelin in Anti-tumor Effect
Volume: 8 Issue: 1
Author(s): Lu Wen and Yan Chen
Affiliation:
Keywords: Anti-tumor, Bcl-xl, Bcl-2, Cyclin D1, Deguelin, IκBα, NF-κB, NPM, NUPs, pRb, SRC-3, Survivin
Abstract: Deguelin is the major active ingredient and principal component in cube resin, derived from Lonchocarpus utilis and used as a botanical insecticide and pesticide in Africa, South America and China. A growing body of evidence indicates that deguelin has a very strong anti-tumor effect on malignant cells without compromising normal cells. As a complex natural extract, deguelin interacts with various molecular targets to exert its anti-tumor properties at nanomolar levels. This current review delineates the molecular mechanism of the anti-tumor activities of deguelin in malignancies. Our research shows that the multiple and extensive biological effects of deguelin are mediated via interactions with target points involved in cell proliferation pathways (cyclin D1, pRb), cell apoptosis pathways (NF-κB, IκBα, Bcl-2, Bcl-xl, survivin), the nucleophosmin and nucleoporins pathways (Nup88, Nup98, Nup214), as well as through the regulation of steroid receptor co-activator SRC-3 and DNA Topoisomerase. In addition, deguelin holds a promising efficacy for reversing drug resistance.
Export Options
About this article
Cite this article as:
Wen Lu and Chen Yan, Molecular Mechanism of Deguelin in Anti-tumor Effect, Current Pharmaceutical Analysis 2012; 8 (1) . https://dx.doi.org/10.2174/157341212798995467
DOI https://dx.doi.org/10.2174/157341212798995467 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Osteoimmunology and Beyond
Current Medicinal Chemistry Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Current Medicinal Chemistry Cellular Senescence and Anti-Cancer Therapy
Current Drug Targets Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients
Cardiovascular & Hematological Disorders-Drug Targets Detection of Clonal Immunoglobulin and T-Cell Receptor Gene Recombination in Hematological Malignancies: Monitoring Minimal Residual Disease
Cardiovascular & Hematological Disorders-Drug Targets The Role of Intestinal Microbiota in Graft versus Host Disease
Mini-Reviews in Medicinal Chemistry Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone
Recent Patents on Anti-Cancer Drug Discovery Corticoisteroid-Induced Apoptosis in Hematological Malignancies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Balance between von-Willebrand Factor and its Cleaving Protease ADAMTS13: Biomarker in Systemic Inflammation and Development of Organ Failure?
Current Molecular Medicine Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery Possible Mechanisms of Lymphoma Development in Sjogren’s Syndrome
Current Immunology Reviews (Discontinued) The Natural Tumor Suppressor Protein Maspin and Potential Application in Non Small Cell Lung Cancer
Current Pharmaceutical Design Phosphoproteomics as a Promising Tool for Broadening the Analysis of Clinical Samples and for the Fight Against Cancer Disease
Current Pharmaceutical Analysis Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets